These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 21729712

  • 21. New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone.
    Latysheva AS, Zolottsev VA, Veselovsky AV, Scherbakov KA, Morozevich GE, Pokrovsky VS, Novikov RA, Timofeev VP, Tkachev YV, Misharin AY.
    Steroids; 2020 Jan; 153():108534. PubMed ID: 31678134
    [Abstract] [Full Text] [Related]

  • 22. N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
    Brossard D, Zhang Y, Haider SM, Sgobba M, Khalid M, Legay R, Duterque-Coquillaud M, Galera P, Rault S, Dallemagne P, Moslemi S, El Kihel L.
    Chem Biol Drug Des; 2013 Nov; 82(5):620-9. PubMed ID: 23906044
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E, Zauhar RJ.
    J Chem Inf Model; 2012 Oct 22; 52(10):2670-83. PubMed ID: 22924551
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
    Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ, Sharifi N.
    Nature; 2015 Jul 16; 523(7560):347-51. PubMed ID: 26030522
    [Abstract] [Full Text] [Related]

  • 30. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
    Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ.
    J Clin Oncol; 2010 Mar 20; 28(9):1481-8. PubMed ID: 20159824
    [Abstract] [Full Text] [Related]

  • 31. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y, Rosenberg JE.
    Drug Des Devel Ther; 2012 Mar 20; 6():13-8. PubMed ID: 22291466
    [Abstract] [Full Text] [Related]

  • 32. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP.
    Cancer Res; 2011 Oct 15; 71(20):6503-13. PubMed ID: 21868758
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
    Wang X, Huang Y, Christie A, Bowden M, Lee GS, Kantoff PW, Sweeney CJ.
    Clin Cancer Res; 2015 Dec 15; 21(24):5578-87. PubMed ID: 26289068
    [Abstract] [Full Text] [Related]

  • 36. 17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.
    Qiao Y, Zhang ZK, Cai LQ, Tan C, Imperato-McGinley JL, Zhu YS.
    Prostate; 2007 Dec 01; 67(16):1719-28. PubMed ID: 17879940
    [Abstract] [Full Text] [Related]

  • 37. CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
    Yin L, Hu Q.
    Nat Rev Urol; 2014 Jan 01; 11(1):32-42. PubMed ID: 24276076
    [Abstract] [Full Text] [Related]

  • 38. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
    Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N.
    Nature; 2016 May 26; 533(7604):547-51. PubMed ID: 27225130
    [Abstract] [Full Text] [Related]

  • 39. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
    Attard G, Reid AH, Olmos D, de Bono JS.
    Cancer Res; 2009 Jun 15; 69(12):4937-40. PubMed ID: 19509232
    [Abstract] [Full Text] [Related]

  • 40. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
    Grigoryev DN, Long BJ, Nnane IP, Njar VC, Liu Y, Brodie AM.
    Br J Cancer; 1999 Oct 15; 81(4):622-30. PubMed ID: 10574247
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.